Evolving immunotherapeutic strategies in bladder and renal cancer

Postgraduate Medical Journal

Volumn 80, Issue 944, 2004, Pages 320-327

  Griffiths, T R L ^a   Mellon, J K ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CYTOKINE; FAS LIGAND; FLUOROURACIL; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEDROXYPROGESTERONE; RETINOIC ACID; TAMOXIFEN; THALIDOMIDE; VINBLASTINE;

ACTIVE IMMUNIZATION; APOPTOSIS; BLADDER CANCER; BOLUS INJECTION; CANCER RISK; CANCER SURVIVAL; CELL ACTIVITY; CELL TRANSFER; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOKINE RELEASE; DOWN REGULATION; DRUG DOSE REGIMEN; EFFECTOR CELL; HIGH RISK POPULATION; HUMAN; IMMUNE SYSTEM; KIDNEY CANCER; KIDNEY CARCINOMA; LYMPHOCYTIC INFILTRATION; LYMPHOKINE ACTIVATED KILLER CELL; METASTASIS; NEPHRECTOMY; PASSIVE IMMUNIZATION; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CARCINOMA, RENAL CELL; CYTOKINES; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 3042646672     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2003.013508     Document Type: Review

References (60)

1. Patel NP, Lavengood RW. Renal cell carcinoma: natural history and results of treatment. J Urol 1978;119:722-6.
2. Mickisch GH, Garin A, van Poppel H, et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon-alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70.
3. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9.
4. Oosterlinck W, Kurth KH, Schroder F, et al. A prospective European Organisation for Research and Treatment of Cancer Genitourinary Group randomised trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in a single stage T1 papillary carcinoma of bladder. J Urol 1993;149:749-52.
5. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996;155:1233-8.
6. Utz DC, Hanash KA, Farrow GM. The plight of the patient with carcinoma in situ of the bladder. J Urol 1970;111:160-4.
7. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomised clinical trials. J Urol 2002;168:1964-70.
8. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975;53:27-42.
9. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5.
10. Burnet FM. Immunological surveillance in neoplasia. Transplant Rev 1971;7:3-25.
11. Semour K, Pettis S, O'Flaherty E, et al. Selection of metastatic tumour phenotypes by host immune systems. Lancet 1999;354:1989-91.
12. Levin I, Klein T, Golstein J, et al. Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival. Cancer 1991;68:2591-4.
13. Keating PJ, Cromme FV, Duggan-Keen M, et al. Frequency of downregulation of individual HLA-A and -B aleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995;72:405-11.
14. Pettit SJ, Ali S, O'Flaherty E, et al. Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD+ T cell activation in vitro. Clin Exp Immunol 1999;116:48-56.
15. Shah AH, Lee C. TGF-beta-based immunotherapy for cancer: breaching the tumour firewall. Prostate 2000;45:167-72.
16. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983 to 1993. Semin Oncol 1995;22:42-60.
17. Goldstein L, Galski H, Fojo A, et al. Expression of a multi-drug resistance gene in human tumours (abstract). Proc Am Assoc Cancer Res 1988;29:298.
18. Bukowski RM. Immunotherapy in renal cell carcinoma. Oncology 1999;13:801-10.
19. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14-17.
20. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(suppl):S55-7.
21. Gold PJ, Thompson JA, Markowitz DR, et al. Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2. Cancer J Sci Am 1997;3(suppl 1):S85-91.
22. Yang JC, Rosenberg SA. An ongoing prospective randomised comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 1997;3(suppl 1):S79-84.
23. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998;338:1265-71.
24. Chikkala NF, Lewis I, Ulchaker J, et al. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine activayed killer activity: analysis at the effector and precursor level. Cancer Res 1990;50:1176-82.
25. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Group Francais d'Immunotheapie. N Engl J Med 1998;338:1272-8.
26. Atzpodien J, Kirchner H, Hanninen EL, et al. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer 1993;29A(suppl 5):S6-8.
27. Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomised clinical trial. Br J Cancer 2001;85:1130-6.
28. Negrier S, Caty A, Lesinple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000;18:4009-15.
29. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomised trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-67.
30. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of alfa-2a with or without 13-cis retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:2972-80.
31. Sasamura H, Takahashi A, Miyao A, et al. Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer 2002;86:768-73.
32. Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82:812-7.
33. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978;120:148-52.
34. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
35. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 2001;345:1711-2.
36. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomised trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-32.
37. Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomised, phase III trial of CD8(+) tumour-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999;17:2521-9.
38. Santarosa M, Favaro D, Quaia M, et al. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer 1997;33:873-7.
39. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-8.
40. Pearl R. Cancer and tuberculosis. Am J Hyg 1929;9:97.
41. Zbar B, Rapp HJ. Immunotherapy of guinea pig cancer with BCG. Cancer 1974;34:1532-40.
42. Bloomberg SD, Brosman SA, Hausman MS, et al. The effects of BCG on the dog bladder. Invest Urol 1975;12:423-7.
43. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumours. J Urol 1976;116:180-3.
44. Luftenegger W, Ackermann DK, Futterlieb A, et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomised study in patients with recurrent superficial bladder tumours. J Urol 1996;155:483-7.
45. Zlotta AR, Drowart A, Van Vooren JP, et al. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette Guerin during intravesical treatment of superficial bladder cancer. J Urol 1997;157:492-8.
46. Matzinger P. An innate sense of danger. Semin Immunol 1998;10:399-415.
47. Saint F, Patard JJ, Maille P, et al. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol 2001;166:2142-7.
48. Vegt PD, Witjes JA, Witjes WP, et al. A randomised study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995;153:929-33.
49. Lamm DL, van der Meijden AP, Akaza H, et al. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness, and what are their limitations and uses? Int J Urol 1995;2(suppl 2):23-35.
50. Witjes JA, Caris CT, Mungan NA, et al. Results of a randomised phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol 1998;160:1668-71.
51. Bouffioux C. Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group. Scand J Urol Nephrol Suppl 1991;138:167-77.
52. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomised Southwest Oncology study. J Urol 2000;163:1124-9.
53. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organisation (or Research and Treatment of Cancer, and Medical Research Council randomised clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group, and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996;156:1934-40.
54. Griffiths TR, Charlton M, Neal DE, et al. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002;167:2408-12.
55. Martinez Pineiro JA, Flores N, Isorna S, et al. Long-term follow-up of a randomised prospective trial comparing a standard 81 mg dose of intravesical bacillus Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89:671-80.
56. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumours. J Urol 2003;169:1706-8.
57. Vegt PD, van der Meijden AP, Sylvester R, et al. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organisation for Research and Treatment of Cancer Protocol 30911. J Urol 1997;157:1246-9.
58. Morales A, Chin JL, Ramsey EW. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 2001;166:1633-7.
59. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001;166:1300-4.
60. Luo Y, Chen X, Han R, et al. Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 2001;123:264-70.